April 4, 2012European Journal of Cardio-Thoracic Surgery
Transapical aortic valve implantation using a new self-expandable bioprosthesis (ACURATE TA™): 6-month outcomes†
Population
40 high-risk elderly patients, mean age 83.2 ± 4.0, 60.0% female, mean logistic EuroSCORE 21.2 ± 10.8%, mean…
Design
Case_series
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Short-term performance of ACURATE TA appears acceptable in high-risk patients; hypothesis-generating pending randomized comparisons.
Structured PICO
P
Population
40 high-risk elderly patients, mean age 83.2 ± 4.0, 60.0% female, mean logistic EuroSCORE 21.2 ± 10.8%, mean STS score 9.0 ± 4.7%
I
Intervention
Transapical aortic valve implantation using the ACURATE TA self-expandable bioprosthesis
O
Outcome
6-month outcomes including survival, valve function (mean aortic gradient, paravalvular leakage), device success, and safety profilecomposite
The ACURATE TA transapical aortic bioprosthesis demonstrated stable valve function, low rates of paravalvular leakage, and acceptable 6-month survival in high-risk elderly patients.
Cite This Study
Kempfert et al. (2012) studied this question.